Lower Level Of Innovation Could Undermine Expedited Approval Pathways
Executive Summary
A Health Affairs study notes that the rate of serious post-marketing safety concerns has risen while PDUFA has pushed down drug review times, feeding into concerns about the increasing use of expedited approvals.